Update on funding and total voting rights

AI SummaryClose X

Allergy Therapeutics plc has secured a new £40 million senior secured facility from Hayfin, replacing an uncommitted £20 million facility, which it intends to fully draw down to provide at least 12 months of working capital. This funding, alongside the recent launch of Grassmuno in Germany, supports the company's focus on its proposed Hong Kong listing. Following the full drawdown, Allergy Therapeutics will have £60 million in debt outstanding. Hayfin has also exercised all its warrants and subscription rights on a cashless basis, resulting in the issuance of 191,089,599 new ordinary shares, bringing their total interest to 3.02% of the company's enlarged issued share capital of 6,332,529,550 ordinary shares. The repayment date for the facilities is contingent on the completion of the Hong Kong listing by December 31, 2026, extending it to February 20, 2031, otherwise it defaults to October 16, 2029.

Disclaimer*

UK 100

Latest directors dealings